The leading funder of multiple myeloma research
As the leading funder of multiple myeloma research, the MMRF has supported more than 380 research grants at over 135 institutions worldwide. The MMRF supports innovative research efforts in the most promising areas of multiple myeloma research through several grant-making programs.
We remain committed to supporting researchers who have more than five years experience in blood cancer research as well as attracting younger scientists to enter the myeloma research field to build the next generation of scientific leaders.
The MMRF welcomes proposals on any and all multiple myeloma related topics to the traditional Research Grant Award programs and from biotech companies with investigational agents for multiple myeloma. For traditional research grants, applications are accepted from non-profit institutions and universities in the United States and internationally. Program guidelines and applications are available approximately 6-8 weeks prior to the submission deadline.
The MMRF ImmunoOncology in Multiple Myeloma Innovations program RFA:
The Multiple Myeloma Research Foundation (MMRF) is pleased to announce a new Clinical and Translational research program to investigate novel, hypothesis-driven, ImmunoOncology (IO) strategies for Multiple Myeloma. Currently, the IO treatment landscape features a wide array of approved and investigational IO strategies, presenting a significant challenge of combining and sequencing these agents for the optimal clinical response in the appropriate patient populations.
The MMRF ImmunoOncology in Multiple Myeloma Innovations program RFA will support innovative, hypothesis-driven clinical trials that are paired with correlative studies designed to demonstrate mechanisms of action or resistance, biomarkers for patient selection, and identification of ancillary targets.
The MMRF encourages the submission of collaborative projects involving academic institutions and pharmaceutical industry partners.
2019 Myeloma Immune Translational Research Accelerator Program RFA:
The Multiple Myeloma Research Foundation (MMRF) is pleased to announce a new translational research program focused on advancing our understanding of patient immunity in myeloma disease biology. The overall goal of this award is to support cutting-edge immune translational research projects that explore clinically relevant questions on immune therapy and accelerate immune precision medicine for multiple myeloma patients.
The MMRF seeks proposals exploring clinically relevant translational research questions that will improve our understanding of cellular therapies in myeloma and accelerate the development of the next wave of such agents for our patients. The specific research areas of interest for this grant include, but are not limited to: mechanisms of response and resistance to ACTs, next generation cellular therapy, constructs and delivery systems, novel ACT targets, and novel cellular therapies biomarkers and diagnostics. Applications for the 2019 Myeloma Immune Translational Research Accelerator Program are due Friday, June 28, 2019.
Research Fellow Awards:
The Multiple Myeloma Research Foundation (MMRF) seeks proposals for the MMRF 2020 Research Fellow Award Program, an initiative supporting researchers at the post-doctorate, medical fellow or junior faculty levels working under the supervision or guidance of a research mentor in the multiple myeloma field. Applications for the MMRF 2020 Research Fellow Award Program are due Friday, August 28th, 2020. The goal of this initiative is to engage and support young investigators entering the field of multiple myeloma while advancing the understanding of myeloma disease biology and disease risk, treatment and response and drug resistance. Proposals may request up to $75,000 for one (1) year.
MMRF Research Fellow Award Program Fosters Next Generation of Myeloma Researchers
The Multiple Myeloma Research Foundation has named the recipients of the 2018 MMRF Research Fellow Award Program. This program aims to prepare and support the next generation of young investigators who are at the forefront of research into myeloma disease biology, patient response to treatment and drug resistance and the advancement of precision medicine in the field of myeloma.
The 2019 Research Fellow Award Winners are:
Benjamin Barwick PhD (Emory)
"Epigenetic Analysis of Multiple Myeloma CoMMpass Specimens”
Emine Gunes, PhD (City of Hope)
“Targeting CD84 immunosuppression in Multiple Myeloma”
Oisun Jung, PhD (U. Wisconsin- Madison)
“Targeting immunosuppression in Multiple Myeloma”
Helen Tanton, PhD (DFCI)
“Investigating the role of the Cyclophilin A-CD147 axis in multiple myeloma”
Ibai Goicoechea, PhD (University of Navarre)
“Circulating myeloma cells: a new model to understand disease dissemination”